Replies to post #242613 on Biotech Values

[ancientacid]

About the #2 on that list; Keytruda, keep an eye open on ways to find new synergetic paths to maintain an edge compared to biosimilars.

One might wonder if it's just a coincidence Merck offered Keytruda to a small swedish company in the oncology-sector for further study..?
https://bioinvent.com/media/press-releases/mfnsingle/?slug=bioinvent-announces-second-clinical-trial-collaboration-and-supply-agreement-to-evaluate-bi-1808-in-combination-with-keytruda-r-pembrolizumab-in-patients-with-advanced-solid-tumors-468bbc81